Skip to content
value.today

Immunomic Therapeutics, Inc.

Formerly Immunomic Therapeutics Delaware, Inc., Immunomic Therapeutics, Inc. (a Maryland corporation)

Total raised
$100 M
8 rounds on record
Latest round
$7 M
May 2025
First round on record
Aug 2011
Today
Private
No later event on record

Funding rounds

8 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Immunomic Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2025$7 MNo. 8$2 to $10 million

Immunomic Therapeutics, Inc.: Raise no. 8, May 2025

Investors in this round

1 investor had bought by the notice of Jun 2, 2025: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $16 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dong-Gun Kim · Executive Officer, Director
  • James Wishart · Director
  • Ki-Hong Ahn · Director
  • Matthew Chang · Director
  • Robert Ahlgren · Director
  • Steve Park · Director
  • Yang Gon Jin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Erin Duffy, Director, Finance. Source: SEC Form D, newest notice filed Jun 2, 2025. Read the notice at the SEC.

equitySEC
Jan 2024$3 MNo. 7$2 to $10 million

Immunomic Therapeutics, Inc.: Raise no. 7, Jan 2024

Investors in this round

1 investor had bought by the notice of Apr 10, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $21 M offered; $18 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • C. Eric Winzer · Executive Officer
  • Dong-Gun Kim · Executive Officer, Director
  • James ERIC Wishart · Director
  • Ki-Hong ERIC Ahn · Director
  • Matthew ERIC Chang · Director
  • Michael ERIC Lack · Director
  • Robert ERIC Ahlgren · Director
  • Ronald ERIC Thiboutot · Director
  • Steve ERIC Park · Director
  • Yang Gon ERIC Jin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by C. Eric Winzer, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 10, 2024. Read the notice at the SEC.

equitySEC
Feb 2020$78 MNo. 6$50 to $250 million

Immunomic Therapeutics, Inc.: Raise no. 6, Feb 2020

Investors in this round

6 investors had bought by the notice of Jan 14, 2021: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$78 M of $78 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,109,129
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • C. Eric Winzer · Executive Officer, Director · Chief Financial Officer and Director
  • William G. Hearl · Executive Officer, Director · Chief Executive Officer and Director
  • Alex S Kim · Director
  • Arlo P. Mcginn · Director
  • Hyuk Joo P. Jee · Director
  • James W. Wishart · Director
  • Michael D. Lack · Director
  • Ronald P. Thiboutot · Director
  • Yang-Gon P. Jin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “The individual also received warrants to purchase 621,826 shares at $5.00 per share.”

Signed by C. Eric Winzer, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Jan 14, 2021. Read the notice at the SEC.

equity, optionsSEC
Apr 2014$1 MNo. 5Under $2 million

Immunomic Therapeutics, Inc.: Raise no. 5, Apr 2014

Investors in this round

10 investors had bought by the notice of Apr 24, 2014: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $9 M offered; $8 M still to sell
Smallest investment taken
$100,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
$100,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bernard C Rudnick · Executive Officer, Director · Chief Financial Officer and Director
  • Bernard C. Rudnick · Executive Officer, Director · Chief Financial Officer and Director
  • Bruce F. Mackler · Executive Officer, Director · Vice President for Regulatory Affairs and Director
  • James D. Wishart · Executive Officer, Director · Secretary and Director
  • Teri Jones Heiland · Executive Officer · Vice President--Research and Development
  • William G Hearl · Executive Officer, Director, Promoter · Chief Executive Officer, Director and Founder
  • Michael D. Lack · Director
  • Ronald D. Thiboutot · Director
  • William Barry McDonald · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William G. Hearl, Ceo. Source: SEC Form D, newest notice filed Apr 24, 2014. Read the notice at the SEC.

equitySEC
Dec 2013$7 MNo. 4$2 to $10 million

Immunomic Therapeutics, Inc.: Raise no. 4, Dec 2013

Investors in this round

56 investors had bought by the notice of Oct 15, 2014: 56 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $9 M offered; $2 M still to sell
Smallest investment taken
$10,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$276,000
Finders' fees
none
Paid to its own people
$500,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bernard C Rudnick · Executive Officer, Director · Chief Financial Officer and Director
  • Bruce F. Mackler · Executive Officer, Director · Vice President for Regulatory Affairs and Director
  • James D. Wishart · Executive Officer, Director · Secretary and Director
  • Teri Jones Heiland · Executive Officer · Vice President--Research and Development
  • William G Hearl · Executive Officer, Director, Promoter · Chief Executive Officer, Director and Founder
  • Michael D. Lack · Director
  • Ronald D. Thiboutot · Director
  • William Barry McDonald · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Newport Coast Securities Inc. (CRD 16944) · New York, New YorkSold in CA, IL, NY, OK, PA

Signed by William G. Hearl, Ceo. Source: SEC Form D and 1 amendment, newest notice filed Oct 15, 2014. Read the notice at the SEC.

equitySEC
Jun 2013$3 MNo. 3$2 to $10 million

Immunomic Therapeutics, Inc.: Raise no. 3, Jun 2013

Investors in this round

36 investors had bought by the notice of Jun 12, 2013: 36 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered; $0 M still to sell
Smallest investment taken
$10,000
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
$10,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bernard C Rudnick · Executive Officer · Chief Financial Officer
  • Bruce C Mackler · Executive Officer, Director · Vice President and Director
  • Lisa C Salley · Executive Officer · Chief Operating Officer
  • William G Hearl · Executive Officer, Director, Promoter · Chief Executive Officer, Director and Founder
  • Winston I Lowe · Executive Officer · General Counsel and Secretary of the Board of Directors
  • James I Wishart · Director
  • Ronald I Thiboutot · Director
  • William Barry McDonald · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William G. Hearl, Ceo. Source: SEC Form D, newest notice filed Jun 12, 2013. Read the notice at the SEC.

debt, optionsSEC
Oct 2012$1 MNo. 2Under $2 million

Immunomic Therapeutics, Inc.: Raise no. 2, Oct 2012

Investors in this round

30 investors had bought by the notice of Jun 12, 2013: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered; $0 M still to sell
Smallest investment taken
$10,000
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
$10,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bernard C Rudnick · Executive Officer · Chief Financial Officer
  • Bruce C Mackler · Executive Officer, Director · Vice President and Director
  • Lisa C Salley · Executive Officer · Chief Operating Officer
  • William G Hearl · Executive Officer, Director, Promoter · Chief Executive Officer, Director and Founder
  • Winston I Lowe · Executive Officer · General Counsel and Secretary of the Board of Directors
  • James I Wishart · Director
  • Ronald I Thiboutot · Director
  • William Barry McDonald · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William G. Hearl, Ceo. Source: SEC Form D, newest notice filed Jun 12, 2013. Read the notice at the SEC.

debt, optionsSEC
Aug 2011$2 MNo. 1Under $2 million

Immunomic Therapeutics, Inc.: Raise no. 1, Aug 2011

Investors in this round

60 investors had bought by the notice of Jun 12, 2013: 60 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered; $0 M still to sell
Smallest investment taken
$50,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
$10,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bernard C Rudnick · Executive Officer · Chief Financial Officer
  • Bruce C Mackler · Executive Officer, Director · Vice President and Director
  • Lisa C Salley · Executive Officer · Chief Operating Officer
  • William G Hearl · Executive Officer, Director, Promoter · Chief Executive Officer, Director and Founder
  • Winston I Lowe · Executive Officer · General Counsel and Secretary of the Board of Directors
  • James I Wishart · Director
  • Ronald I Thiboutot · Director
  • William Barry McDonald · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William G. Hearl, Ceo. Source: SEC Form D and 1 amendment, newest notice filed Jun 12, 2013. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Immunomic Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2025).

    SEC Form D · Jun 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2025

That is all the official record says: Immunomic Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Immunomic Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 8 rounds above had up to 60 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Immunomic Therapeutics, Inc.
NameRoleNamed in
Dong-Gun KimExecutive officerJun 2025
C. Eric WinzerExecutive officerApr 2024
William G. HearlChief Executive Officer and DirectorJan 2021
Bernard C RudnickChief Financial Officer and DirectorOct 2014
Bernard C. RudnickChief Financial Officer and DirectorOct 2014
Bruce F. MacklerVice President for Regulatory Affairs and DirectorOct 2014
James D. WishartSecretary and DirectorOct 2014
Teri Jones HeilandVice President--Research and DevelopmentOct 2014
William G HearlChief Executive Officer, Director and FounderOct 2014
Bruce C MacklerVice President and DirectorJun 2013
Lisa C SalleyChief Operating OfficerJun 2013
Winston I LoweGeneral Counsel and Secretary of the Board of DirectorsJun 2013
Teri Barry HeilandVice President of Research and DevelopmentMar 2012
Dong-Gun KimDirectorJun 2025
James WishartDirectorJun 2025
Ki-Hong AhnDirectorJun 2025
Matthew ChangDirectorJun 2025
Robert AhlgrenDirectorJun 2025
Steve ParkDirectorJun 2025
Yang Gon JinDirectorJun 2025
James ERIC WishartDirectorApr 2024
Ki-Hong ERIC AhnDirectorApr 2024
Matthew ERIC ChangDirectorApr 2024
Michael ERIC LackDirectorApr 2024
Robert ERIC AhlgrenDirectorApr 2024
Ronald ERIC ThiboutotDirectorApr 2024
Steve ERIC ParkDirectorApr 2024
Yang Gon ERIC JinDirectorApr 2024
Alex S KimDirectorJan 2021
Arlo P. McginnDirectorJan 2021
C. Eric WinzerChief Financial Officer and DirectorJan 2021
Hyuk Joo P. JeeDirectorJan 2021
James W. WishartDirectorJan 2021
Michael D. LackDirectorJan 2021
Ronald P. ThiboutotDirectorJan 2021
William G. HearlChief Executive Officer and DirectorJan 2021
Yang-Gon P. JinDirectorJan 2021
Bernard C RudnickChief Financial Officer and DirectorOct 2014
Bernard C. RudnickChief Financial Officer and DirectorOct 2014
Bruce F. MacklerVice President for Regulatory Affairs and DirectorOct 2014